SCHEMBL25397254

SCHEMBL25397254

O=C1CC[CH]CN1Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.56
DDB1 Q16531 1/20 0.47
CRBN Q96SW2 1/20 0.47
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 4/20 0.42
POLB P06746 3/20 0.42
MEN1 O00255 3/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
F2 P00734 1/20 0.42
PLG P00747 1/20 0.42
ELANE P08246 1/20 0.42
CTSG P08311 1/20 0.42
CMA1 P23946 1/20 0.42
CTRC Q99895 1/20 0.42
GSK3A P49840 2/20 0.42
GSK3B P49841 2/20 0.42
NPC1 O15118 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25226566 0.84 L3MBTL1 (0.54) L3MBTL1DDB1CRBNHPGDTSHR
SCHEMBL2181115 0.81 L3MBTL1 (0.50) L3MBTL1DDB1CRBNHPGDTSHR
SCHEMBL7389188 0.77 L3MBTL1 (0.73) L3MBTL1DDB1CRBNHPGDTSHR
SCHEMBL17395293 0.76 L3MBTL1 (0.65) L3MBTL1DDB1CRBNHPGDTSHR
SCHEMBL17395296 0.76 L3MBTL1 (0.65) L3MBTL1DDB1CRBNHPGDTSHR
SCHEMBL9058751 0.74 L3MBTL1 (0.59) L3MBTL1DDB1CRBNHPGDTSHR
SCHEMBL3313053 0.74 L3MBTL1 (0.50) L3MBTL1DDB1CRBNHPGDTSHR
SCHEMBL180739 0.74 L3MBTL1 (0.86) L3MBTL1DDB1CRBNKMT2APOLB
SCHEMBL596252 0.73 L3MBTL1 (0.96) L3MBTL1DDB1CRBNKMT2APOLB
Hydrochloric Acid SCHEMBL6818365 0.73 L3MBTL1 (0.83) L3MBTL1DDB1CRBNKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023177233-A1 NOVEL COMPOUND AND USE THEREOF FOR INHIBITING CHECKPOINT KINASE 2 (주)아름테라퓨틱스 2023-09-21 WO disclosed